Appendix B. Sources of evidence considered by the Committee

Appendix B. Sources of evidence considered by the Committee

1. The following documentation and opinion were made available to the Committee:

A. Assessment report prepared by NHS Centre for Reviews and Dissemination and Centre for Health Economics: A Systematic Review Update of the Clinical Effectiveness and Cost Effectiveness of Glycoprotein IIb/IIIa Antagonists and A Cost-effectiveness Model Comparing Alternative Management Strategies for the Use of Glycoprotein IIb/IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes.

B. Manufacturer/sponsor submissions from:

  • Lilly

  • Schering Plough

  • MSD

C. Professional/specialist group submissions from:

  • British Cardiac Society and Royal College of Physicians (joint submission)

  • Royal College of General Practitioners

  • Department of Health and the Welsh Assembly Government

D. Patient/carer group submissions from:

  • British Heart Foundation

E. Expert perspective:

  • Dr J McLenachan, Dept of Cardiology, Leeds General Infirmary

  • Dr Charles Knight, Cardiology Dept, King George Hospital